Injecting Tirzepatide: What to Decide Before You Pick Up the Pen

Tirzepatide (Mounjaro) is injected once weekly into subcutaneous fat, the abdomen, outer thigh or upper arm are all licensed sites.
Each Mounjaro KwikPen contains four weekly doses; a new needle is attached before every injection.
Rotating your injection site each week reduces the risk of localised skin reactions and lumpiness beneath the skin.
The pen should be stored in the fridge (2–8°C); bring it to room temperature for a short while before injecting, check the Patient Information Leaflet for the exact timing and temperature window.

Injecting tirzepatide for the first time raises a handful of practical decisions — site, preparation, what to do if something looks wrong — that are worth settling before you uncap the pen. Mounjaro is given as a once-weekly subcutaneous injection, delivered just beneath the skin using a pre-filled KwikPen. Most people find the process straightforward within one or two doses, but getting the details right from the start reduces discomfort and supports consistent absorption. These are prescription-only medicines: a GPhC-registered prescriber reviews every patient before treatment begins, and your Patient Information Leaflet is the definitive source for anything dose-specific.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

The decisions that make each injection safer and more comfortable

Choosing where to inject: site, rotation, and what actually matters

Three body areas are licensed for tirzepatide injections, including the abdomen (avoiding a 5 cm radius around the navel), the outer thigh, and the back of the upper arm. There is no clinical hierarchy among them, absorption is comparable across all three, so the right site is largely the one you can reach confidently and consistently.

What does matter is rotation. Injecting repeatedly into the same small patch of skin causes lipohypertrophy, a build-up of fibrous tissue that slows absorption unpredictably. A practical approach is to divide each site into segments and move around them week by week (left abdomen one week, right the next, for example) rather than landing in exactly the same spot. If you are also taking insulin for type 2 diabetes, keep the tirzepatide and insulin injections in different areas; discuss this with your prescriber.

Many patients worry that the thigh is somehow more painful or less effective. That concern is understandable, but there is no evidence to support it. The thigh site is as valid as any other, and some people find it the easiest to self-administer when injecting alone. Personal preference, guided by a bit of early experimentation, usually settles the question quickly.

For a visual walkthrough of site selection and pen handling, the tirzepatide injection video guide on this site covers the process step by step.

Preparing the pen: the checks worth making every time

Before each injection, take the pen out of the fridge and allow it to reach room temperature. Injecting cold liquid is the most common cause of stinging, a simple fix that many people only discover after a few uncomfortable doses. The exact time and temperature window is specified in the Patient Information Leaflet; follow that rather than a general rule of thumb.

Check the solution through the pen's viewing window. It should be clear to slightly yellow and free of particles. If it looks cloudy, contains visible flecks, or has changed colour, do not use it. Contact your prescriber or our clinical support team if you are unsure.

Attach a fresh needle before every injection. Reusing needles blunts the tip, increases injection-site discomfort, and raises the risk of contamination. Needles should never be recapped after use. Replacement needles are available separately if you need them. Used needles and pens go into a sharps container (never into household waste) and your local pharmacy or GP surgery can advise on collection.

Clean the chosen skin area with an alcohol swab and allow it to dry fully before injecting. Wet skin traps residual alcohol under the needle and can sting. That step takes about ten seconds and is worth not rushing. The full pen guide covers the sequence in more detail, including how to prime and reset the pen correctly.

During and after the injection: what the experience is usually like

Pinch a small fold of skin, insert the needle at a 90-degree angle, and press the plunger slowly and steadily. Hold the pen in place for ten seconds after the plunger reaches the bottom, this allows all of the dose to be delivered before the needle is withdrawn. Pulling out too quickly is a common reason for finding a small amount of liquid on the skin after injection; it does not necessarily mean the full dose was missed, but if you are regularly seeing this, mention it to your prescriber.

Mild redness, slight bruising or a small raised area at the injection site are normal and usually resolve within a day or two. These are listed among the common reactions in the NHS tirzepatide medicines page, alongside the broader side-effect profile of the medication. Persistent nodules, significant swelling, or signs of infection (warmth, pus, spreading redness) are not normal and should be reviewed promptly.

If you miss a dose, the guidance is in the Patient Information Leaflet and from your prescriber, this page does not substitute for that. What is consistent across most missed-dose situations is that the weekly schedule, rather than doubling up, is what matters. The detailed injection guide covers missed-dose framing and the broader routine in more practical terms.

Cost context and getting started under clinical supervision

Understanding how to inject tirzepatide correctly is one part of the picture; having access to a genuine, regulated supply is the other. Since Eli Lilly adjusted UK list prices in late 2025, private treatment costs have varied considerably by dose and provider, the context behind that price change is covered separately if you want the detail. What has not changed is the importance of obtaining tirzepatide through a pharmacy you can verify on the GPhC register: counterfeit pens seized by the MHRA have contained substances that caused hospitalisations, and the injection technique described on this page only applies to genuine product from the licensed supply chain.

At nume, every patient is reviewed by a named GPhC-registered Independent Prescriber before treatment is issued, a real clinician, not an automated process. Once approved, treatment is dispatched the same day for free next-working-day delivery. If you are considering tirzepatide for weight management and want to understand whether it might be appropriate for you, the best starting point is a clinical conversation.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions